T0	Participants 85 193	Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
T1	Participants 352 477	patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy.
T2	Participants 478 580	Patients with epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations
T3	Participants 868 966	1,253 patients with metastatic NSCLC previously treated with a platinum-based combination therapy.
T4	Participants 1920 2053	treatment of patients with metastatic non-small cell lung cancer whose disease has progressed on or after platinum-based chemotherapy
T5	Participants 2104 2148	safety in patients with squamous cell tumors
T6	Participants 2160 2189	treatment in elderly patients
T7	Participants 2219 2349	effects in patients with tumors harboring epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations